Pacemakers Market - By Product, By Technology, By End Use - Global Forecast, 2025 - 2034

Pacemakers Market Size

The global pacemakers market was valued at USD 5.7 billion in 2024. The market is expected to grow from USD 5.9 billion in 2025 to USD 9 billion in 2034, at a CAGR of 4.8% from 2025 to 2034, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the increasing prevalence of cardiovascular diseases, favorable reimbursement policies, and rising adoption of minimally invasive procedures, among others.

Pacemakers provide life-saving assistance for patients with heart rhythm disorders. Industry leaders include Abbott, Medtronic, and Boston Scientific, among others, driving innovation through innovative designs, longer battery life, and remote monitoring features.
 

The market has increased from USD 5.1 billion in 2021 and reached USD 5.5 billion in 2023, with a historic growth rate of 3.6%. This growth was primarily driven by rising cardiovascular disease prevalence, technological advancements in pacemakers, and increasing adoption of remote patient monitoring solutions.
 

MRI-compatible pacemakers have gained significant traction. These devices allow patients to safely undergo magnetic resonance imaging, which is crucial for diagnosing other conditions post-implantation. Additionally, Bluetooth-enabled and AI-powered pacemakers are revolutionizing cardiac care by enabling real-time remote monitoring, reducing emergency visits by up to 30%, and allowing clinicians to adjust device settings based on patient activity and rhythm patterns.
 

Moreover, battery technology has seen significant improvements, with modern pacemakers offering lifespans of up to 20 years, which substantially reduces the frequency of replacement procedures. In 2025, Microport launched a new version of the TEN pacemaker. This device is designed with a compact size, long battery life, automation, and physiological performance.
 

Pacemakers are medical devices that generate electrical impulses to regulate the heartbeat when the heart's natural electrical conduction system is not functioning properly, playing a critical role in cardiac rhythm management.
 

Pacemakers Market Trends

The rising global burden of cardiovascular diseases (CVDs) continues to be a major driver for growth in the pacemakers market.
 

• CVDs remain the leading cause of death worldwide, accounting for an estimated 17.9 million deaths annually, or 32% of all global deaths, according to the World Health Organization. Of these, 85% are attributed to heart attacks and strokes, highlighting the urgent need for effective cardiac rhythm management solutions.
   
• The incidence of arrhythmias, bradycardia, tachycardia, and congestive heart failure (CHF), conditions commonly treated with pacemakers, is rising steadily. As per a 2023 National Institutes of Health (NIH) report, ventricular tachycardia and fibrillation are responsible for nearly 300,000 sudden cardiac deaths annually in the U.S., representing half of all cardiac-related mortalities. This surge in life-threatening rhythm disorders is directly contributing to increased hospitalizations and a higher volume of cardiac procedures, thereby driving pacemaker adoption.
   
• Surge in these cardiac anomalies is set to drive the number of hospitalizations and medical procedures, which in turn is projected to drive the adoption of pacemakers. Several factors, including the drastic shift in behavioral risk factors such as unhealthy diet, reduced physical activity, increased tobacco use, and excessive consumption of alcohol, among others, have promoted the prevalence and mortality rate related to cardiovascular diseases.
   

Pacemakers Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the product, the pacemakers market is segmented into implantable pacemakers and external pacemakers. The implantable pacemakers segment accounted for 89.1% of the market in 2024 due to their proven effectiveness in managing chronic heart rhythm disorders such as bradycardia and arrhythmias, their long-term reliability, and increasing adoption of minimally invasive implantation techniques. The segment is expected to exceed USD 7.9 billion by 2034, growing at a CAGR of 4.6% during the forecast period.
 

On the other hand, the external pacemakers segment held a market share of 10.9% in 2024. The growth of this segment can be attributed to its non-invasive nature, making it ideal for temporary pacing in emergency settings, post-operative care, and acute cardiac conditions such as bradycardia and myocardial infarction.
 

• Implantable pacemakers offer continuous pacing, improved patient outcomes, and are preferred for long-term cardiac care, especially among the aging population and those with recurrent rhythm abnormalities.
   
• Moreover, implantable pacemakers are programmable, which means that healthcare providers can adjust the device's settings to meet the specific needs of each patient. This customization allows for precise control of heart rate and rhythm, ensuring that the device responds appropriately to changes in the patient's condition over time. Modern implantable pacemakers are designed to be durable and have a relatively long lifespan. Thus, such advantages associated with the product will lead the market growth.
   

Based on technology, the pacemakers market is segmented into single-chamber pacemakers, dual-chamber pacemakers, and biventricular/CRT pacemakers. The dual-chamber pacemakers segment dominated the market in 2024, accounting for USD 4.1 billion, and is anticipated to grow at a CAGR of 5.2% during the forecast period.
 

• An increase in the number of people suffering from atrioventricular block is benefiting from the use of a dual-chamber pacemaker device. The device has two leads that are placed in the right atrium and right ventricle. After detecting a slow heart rate, these leads function synchronously to mimic the actual physiological function of the atrium and ventricle.
   
• By regulating the timing of atrial and ventricular contractions, a dual-chamber pacemaker optimizes blood flow and cardiac output, potentially leading to better oxygenation of the body's tissues and organs.
   
• The second largest segment, single-chamber pacemakers, held a market share of approximately 20.4% in 2024, driven by their cost-effectiveness, simpler implantation procedures, and suitability for patients with less complex arrhythmias such as bradycardia and heart block. Their widespread use in emergency and temporary pacing scenarios, along with growing adoption in low- and middle-income countries, continues to support steady market demand.
   
• On the other hand, the biventricular/CRT pacemakers segment is expected to expand rapidly, driven primarily by the rising prevalence of heart failure and the growing clinical adoption of cardiac resynchronization therapy (CRT) to improve ventricular coordination and cardiac output.
   

Based on application, the pacemakers market is segmented into congestive heart failure, bradycardia, arrhythmias, tachycardia, and other applications. The congestive heart failure segment was anticipated to be worth USD 2.1 billion in 2024.
 

• This is primarily attributable to the growing incidence rate of recurrent arrhythmia due to factors such as sedentary lifestyle disorders and the increasing incidence of heart attacks across the globe.
   
• For instance, as per the Lancet study, in 2021, atrial fibrillation (AF) was the most frequent cardiac arrhythmia worldwide, with 37.6 million cases and an attributable 287,200 deaths. Moreover, the worldwide prevalence of atrial fibrillation has increased by 33% during the last 20 years, placing a huge burden across the globe. Thus, the increasing prevalence rate of arrhythmia and related diseases will stimulate the segmental progression during the forecast period.
   
• On the other hand, the bradycardia segment is expected to grow at a 4.6% CAGR. The segment is experiencing rapid growth, fueled by the high clinical prevalence of bradycardia, which often leads to symptoms like fatigue, dizziness, and fainting—necessitating timely intervention with pacemakers.
   
• The third largest segment, arrhythmias, held a market share of approximately 13.8% in 2024, driven by the high global prevalence of abnormal heart rhythms, including atrial fibrillation, ventricular tachycardia, and conduction disorders, which often require pacemaker intervention to restore and maintain normal cardiac function.
   
• The tachycardia segment is witnessing steady growth in the pacemakers market, driven by the rising incidence of ventricular tachycardia and fibrillation, which are major contributors to sudden cardiac death. Additionally, increased hospitalizations due to acute cardiac events, along with growing awareness and early diagnosis of rhythm disorders, are further accelerating the demand for pacing solutions tailored to tachycardia management.
   
• The other applications segment was valued at USD 295.6 million in 2024, driven by the use of pacemakers in managing less common cardiac irregularities such as syncope, hypertrophic cardiomyopathy, and neurocardiogenic disorders, where rhythm stabilization is critical for symptom relief and patient safety.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the pacemakers market is classified into hospitals and clinics, cardiac care centers, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market with a revenue share of 50.3% in 2024 and is expected to reach USD 4.4 billion within the forecast period.
 

• The soaring use of pacemakers in hospital settings delivering rapid and reliable outcomes is estimated to increase patient preference for these healthcare facilities. Additionally, the availability of a broad spectrum of pacemakers for maintaining and regulating cardiac rhythm with proven accuracy is set to drive product preference in hospitals and clinics. Growing admissions with cardiac ailments and growing disease screening initiatives, along with the accessibility to board-certified healthcare professionals, are some other variables that are positively augmenting the growth of the segment.
   
• Cardiac care centers are witnessing steady growth, driven by the rising prevalence of cardiovascular diseases, increasing demand for specialized rhythm management services, and the expansion of advanced diagnostic and therapeutic infrastructure.
   
• The ambulatory surgical centers (ASCs) segment was valued at approximately USD 901.2 million in 2024, driven by the growing preference for minimally invasive procedures, shorter recovery times, and reduced hospitalization costs.
   
• The other end users segment held a market share of approximately 5.6% in 2024, driven by the use of pacemakers in rehabilitation centers, long-term care facilities, and home healthcare settings, where demand is rising for portable cardiac devices that support chronic cardiac care.

Looking for region specific data?

Download Free PDF

North America Pacemakers Market
 

North America dominated the market with the highest market share of 50.9% in 2024.
 

• The U.S. pacemakers market was valued at USD 2.48 billion and USD 2.54 billion in 2021 and 2022, respectively. The market size reached USD 2.67 billion in 2024, growing from USD 2.60 billion in 2023, and is anticipated to grow at a CAGR of 3.3% between 2025 and 2034.
   
• This significant market share is attributed to several factors, such as the presence of major industry players, an upsurge in the demand for cardiovascular devices, a rise in the prevalence of cardiovascular conditions, and the growing number of hospital admissions across the country, among others.
   
• The rising prevalence of adverse events is anticipated to upsurge the adoption rate for better CVD management, including the use of pacemakers and cardiac arrhythmia monitoring devices. This is further driving the entry of new players in the market that are projected to increase over the forecast timeframe. Moreover, various medical device manufacturers that are involved in research and development of modifying pacemakers are also expected to foster the market growth in the region.
  
   

Europe Pacemakers Market
 

Europe market accounted for USD 1.4 billion in 2024.
 

• Europe maintains a strong position in the global pacemakers market, supported by its advanced healthcare infrastructure and high awareness of cardiac health. The region has a well-established network of cardiac care centers and electrophysiology labs, which facilitates early diagnosis and timely intervention for rhythm disorders. Countries like Germany, France, and the UK are leaders in clinical adoption, with widespread use of MRI-compatible and leadless pacemakers.
   
• The aging population across Europe is a major contributor to the rising demand for pacemakers, particularly for conditions like bradycardia and congestive heart failure. Favorable reimbursement policies and government support for cardiac care programs further enhance accessibility. Additionally, ongoing research and innovation in cardiac rhythm management technologies continue to strengthen Europe’s role as a hub for device development and clinical excellence.
  
   

Asia Pacific Pacemakers Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.3% during the analysis timeframe.
 

• Asia Pacific is emerging as one of the fastest-growing regions in the market, driven by a sharp rise in cardiovascular disease prevalence and increasing healthcare investments. Countries such as China, India, Japan, and South Korea are witnessing a surge in demand for cardiac devices due to urbanization, lifestyle changes, and a growing elderly population. Public health initiatives and awareness campaigns are also contributing to early diagnosis and treatment.
   
• The region is seeing rapid adoption of minimally invasive procedures and advanced pacemaker technologies, including leadless and Bluetooth-enabled devices. While rural areas still face challenges in access and affordability, the expansion of private healthcare providers and local manufacturing is helping bridge the gap.
  
   

Latin America Pacemakers Market
 

The Latin America market is expected to experience robust growth over the analysis timeframe.
 

• Countries like Brazil, Mexico, and Argentina are leading in terms of device adoption, with increasing availability of specialized cardiac care services. Government efforts to expand public health coverage and invest in medical technology are helping drive demand.
   
• Despite economic disparities and uneven access in rural regions, the market is benefiting from strategic collaborations between global device manufacturers and local distributors. Educational initiatives and training programs for healthcare professionals are also enhancing procedural capabilities. Latin America’s growing middle class and expanding private healthcare sector are expected to further support market development.
  
   

Middle East and Africa Pacemakers Market
 

The Middle East and Africa market is expected to experience notable growth over the analysis timeframe.
 

• The Middle East and Africa region is gradually gaining traction in the market, fueled by rising incidences of arrhythmias and heart failure. Countries such as Saudi Arabia and the UAE are investing heavily in healthcare modernization, including the establishment of advanced cardiac centers. South Africa also shows promising growth due to its expanding private healthcare network.
   
• Challenges such as limited access in remote areas and regulatory complexities persist but increasing government focus on non-communicable diseases and partnerships with international health organizations are helping improve cardiac care delivery. The adoption of external pacemaker for temporary pacing and the growing use of remote monitoring technologies are contributing to the region’s evolving market landscape.
   

Pacemakers Market Share

Leading industry players such as Abbott, Boston Scientific, Medtronic, BIOTRONIK, and MicroPort hold around 91% of the market share in the competitive market. These companies maintain their leading position by combining strong product lines, business collaborations with healthcare providers, regulatory clearances, and consistent product innovation.
 

Major companies in the pacemakers market are reinforcing their competitive positions by focusing on innovation, including the development of MRI-compatible systems and AI-integrated remote monitoring platforms. These advancements are aimed at improving patient safety, reducing complications, and enhancing long-term outcomes. Companies are also investing in battery-free and bioresorbable pacemakers, which are currently in clinical trials and expected to redefine temporary pacing solutions.
 

Medtronic continues to lead the market with its comprehensive portfolio. The company is also advancing AI-powered programming tools and expanding access through remote monitoring technologies, enabling real-time patient management and reducing hospital readmissions.
 

Abbott is strengthening its position with new innovations. The company is also leveraging Bluetooth-enabled devices and cloud-based platforms to support remote diagnostics and personalized therapy adjustments, aligning with the shift toward outpatient and home-based cardiac care.
 

Boston Scientific is focusing on resynchronization therapy and dual-chamber pacing solutions, with a strong emphasis on minimally invasive procedures and smart device connectivity. Its investments in digital health platforms and physician training programs are helping expand its global footprint, particularly in emerging markets.
 

Meanwhile, other key players such as Biotronik, and MicroPort are investing in next-generation pacing systems, including dual-chamber leadless devices, MRI-safe technologies, and longer-lasting batteries. These companies are also exploring regional partnerships, clinical collaborations, and regulatory fast-tracking to accelerate innovation and expand market access.
 

Pacemakers Market Companies

A few of the prominent players operating in the pacemakers industry include:

• Abbott
• BIOTRONIK
• Boston Scientific
• Lepu Medical
• MEDICO
• Medtronic
• MicroPort
• Oscor
• Osypka Medical
• Pacetronix
• Vitatron

• Abbott

Abbott stands out for its patient-centric innovations and emphasis on connectivity and remote care. Its pacemakers feature Bluetooth-enabled technology, allowing seamless integration with mobile apps and cloud platforms for real-time monitoring and data sharing. This empowers both patients and clinicians with actionable insights and supports outpatient management. Abbott also focuses on modular device architecture, enabling future upgrades and customization, which aligns with the growing demand for personalized cardiac care.
 

• Boston Scientific

Boston Scientific differentiates itself through its expertise in cardiac resynchronization therapy (CRT) and dual-chamber pacing systems. The company emphasizes minimally invasive implantation techniques and smart device connectivity, enhancing procedural efficiency and long-term patient outcomes. Its investment in digital health platforms, physician training, and clinical support tools ensures high adoption rates and strong engagement across healthcare systems, particularly in emerging markets.
 

• Medtronic

Medtronic maintains a competitive edge through its comprehensive portfolio of pacing systems, including advanced MRI-compatible devices and adaptive-rate technologies that respond to patient activity levels. The company is a pioneer in AI-driven programming tools, which optimize device settings based on individual rhythm patterns. Medtronic also leads in remote monitoring infrastructure, offering robust platforms that reduce hospital visits and improve chronic care management.
 

Pacemakers Industry News:

• In May 2024, Medtronic plc announced U.S. Food and Drug Administration (FDA) approval of its Micra AV2 and Micra VR2, the next generation of its industry-leading miniaturized, leadless pacemakers. This product approval helped the company to enhance its product portfolio and business revenue.
   
• In July 2023, Abbott received FDA approval for the AVEIR dual chamber (DR) leadless pacemaker system, marking a significant advancement in the leadless pacemaker market. The AVEIR DR system utilizes advanced communication technology, enabling synchronized cardiac pacing between two leadless pacemakers implanted in the right atrium and right ventricle. This product launch helped the company acquire an enhanced customer base and generate increased business revenue.
   

The pacemakers market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Implantable pacemakers
• External pacemakers

Market, By Technology

• Single-chamber pacemakers
  • Single-chamber ventricular
  • Single-chamber atrial 
• Dual-chamber pacemakers
• Biventricular/CRT pacemakers

Market, By Application

• Congestive heart failure
• Bradycardia
• Arrhythmias
• Tachycardia
• Other applications

Market, By End Use

• Hospitals and clinics
• Cardiac care centers
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE